Annual report for Granules India Ltd. for FY-2020
02-06-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Open Offer - Updates
Granules India Limited - Buyback of fully paid-up equity shares of face value ?1 each ('Equity Shares') through the 'Tender Offer' route, at a price of ?200 (Rupees Two Hundred only) per Equity Share (the 'Buyback Price') for an aggregate amount of up to ?250,00,00,000 (Rupees Two Hundred and Fifty Crore only) ('Buyback')01-06-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Update on the divestment of Company''s stake in Granules OmniChem Private Limited.29-05-2020
GRANULES INDIA LTD.-$ - 532482 - Clarification On The Presence Of NDMA In The Company'S Products
Clarification on the presence of NDMA in the Company's Products28-05-2020
Granules India (171.7): Buy
Accompanied by above average volume, the stock of Granules India jumped 4 per cent on Wednesday. During the rally, it decisively broke a key resistanc20-05-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Earnings Conference call for Q4, FY2019-2020-05-2020
GRANULES INDIA LTD.-$ - 532482 - Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve The Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2020 And The Recommendation Of Final Dividend For The FY 2019-20
GRANULES INDIA LTD.-$has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2020 ,inter alia, to consider and approve Intimation of Board Meeting to consider and approve the audited Financial Results for the fourth quarter and financial year ended March 31, 2020 and the recommendation of final dividend for the FY 2019-2017-05-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited announces approval of Vigabatrin for Oral Solution USP, 500 mg27-04-2020
Granules India share price rises 6% on USFDA nod
Granules now has a total of 26 ANDA approvals from US FDA (24 Final approvals and 2 tentative approvals).24-04-2020
GRANULES INDIA LTD.-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Granules India Limited announces approval of Trospium Chloride ER Capsules, 60 mg24-04-2020